Biron P, Proulx A, Lapointe L, Nadeau R, Tremblay G
Eur J Clin Pharmacol. 1975;8(1):11-4. doi: 10.1007/BF00616409.
Acebutolol (M & B 17,803 A), a new cardioselective beta-adrenergic blocking agent, was given intravenously to 20 selected patients with various cardiac arrhythmias. Cumulative doses ranging from 12.5 to 50 mg were moderately or highly effective in 4 out of 4 patients with sinus tachycardia, 2 out of 3 patients with premature atrial beats, 3 out of 4 patients with premature ventricular beats, 3 out of 5 patients with atrial fibrillation (one was converted to sinus rhythm) and in 2 out of 3 patients with atrial flutter. The drug was ineffective in one patient with atrial tachycardia. Mild systolic hypotension occured in two patients with recent myocardial infarction and there was some aggravation of a preexisting bronchospasm in a patient with congestive heart failure secondary to hyper-thyroidism. It was concluded that acebutolol is a cardioselective beta-blocker which by intravenous route may be useful in the treatment of selected cardiac arrhythmias.
醋丁洛尔(M&B 17803 A)是一种新型的心脏选择性β-肾上腺素能阻滞剂,对20例患有各种心律失常的特定患者进行了静脉给药。累积剂量为12.5至50毫克,对4例窦性心动过速患者中的4例、3例房性早搏患者中的2例、4例室性早搏患者中的3例、5例房颤患者中的3例(1例转为窦性心律)以及3例房扑患者中的2例有中度或高度疗效。该药物对1例房性心动过速患者无效。2例近期心肌梗死患者出现轻度收缩期低血压,1例继发于甲状腺功能亢进的充血性心力衰竭患者原有支气管痉挛有所加重。结论是醋丁洛尔是一种心脏选择性β受体阻滞剂,静脉给药可能对治疗特定的心律失常有用。